OncoMatch/Clinical Trials/NCT06378190
Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology
Is NCT06378190 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CAR-T cells therapy for refractory b-cell lymphoma.
Treatment: CAR-T cells therapy — The goal of this clinical trial is to to evaluate the safety and efficacy of TranspoCART19 in patients with relapsed/refractory B-lymphoma. The main questions it aims to answer are: Maximum tolerated dose (MTD) Response rates Participants will be treated with the investigational medicinal product and will be followed for 36 months.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD19 expression (expression confirmed in tumour biopsy if prior anti-CD19 therapy)
Previous treatment with other anti-CD19 strategies is permitted, provided that CD19 expression has been confirmed in the tumour biopsy.
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-CD19 CAR-T cell therapy
Previous anti-CD19 CAR-T therapy
Lab requirements
Blood counts
adequate bone marrow haematopoietic reserve
Kidney function
calculated glomerular filtration rate < 30 ml/min
Liver function
bilirubin > 2 times upper limit of normal (unless due to Gilbert's syndrome) or transaminases > 2.5 upper limit of normal
Cardiac function
cardiac ejection fraction <40%
Adequate bone marrow haematopoietic reserve. Severe organ involvement, defined as cardiac ejection fraction <40%; diffusing capacity of the lungs for carbon monoxide (DLCO) <40%; calculated glomerular filtration rate <30 ml/min; baseline O2 saturation <92%; bilirubin > 2 times upper limit of normal (unless due to Gilbert's syndrome) or transaminases > 2.5 upper limit of normal.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify